FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order

By ··2 min read

The Federal Trade Commission settled its insulin rebating case against Express Scripts, the Cigna-owned pharmacy benefit manager. The consent order requires formulary, compensation and transparency changes that the FTC estimates will save patients up to $7 billion in out-of-pocket costs over ten years.

The Federal Trade Commission announced on February 4, 2026 that it had reached a settlement with Express Scripts, Inc. and its affiliated entities, the pharmacy benefit manager owned by The Cigna Group through its Evernorth unit. The agreement, formalised as a consent order, resolves Express Scripts' part of the administrative case the agency brought in September 2024 against the three largest PBMs over insulin rebating. The FTC estimates the settlement will cut patients' out-of-pocket drug costs by up to $7 billion over ten years.

The complaint, brought under Section 5 of the FTC Act, alleged that Express Scripts, CVS Health's Caremark Rx and UnitedHealth Group's OptumRx used rebate-driven formulary strategies that artificially inflated insulin list prices. The agency alleged that the PBMs excluded lower list price insulins in favour of high list price, heavily rebated products, shifting costs onto patients whose cost-sharing tracks list price. Under the settlement, Express Scripts must stop preferring high wholesale acquisition cost drug versions on its standard formularies, offer plan sponsors a standard option based on net cost, delink its compensation from manufacturer savings, and move its group purchasing organisation from Switzerland to the United States. The terms extend to pharmaceutical products generally.

The PBMs denied the allegations and filed a countersuit against the agency. A federal district court allowed the FTC's case to proceed in February 2025, and the Eighth Circuit later declined the PBMs' request for an injunction. After the settlement, Express Scripts executives told investors that the agreement largely formalised reforms the company was already making.

The case grew out of an industry-wide FTC inquiry launched in 2022. The agency's July 2024 interim staff report found that the top three PBMs processed nearly 80% of the roughly 6.6 billion prescriptions dispensed by US pharmacies in 2023. A second interim report in January 2025 found that the three PBMs and their affiliated pharmacies earned more than $7.3 billion in dispensing revenue above estimated acquisition costs on specialty generics between 2017 and 2022.

The Express Scripts consent order is now in force. The FTC announced a similar settlement with Caremark on July 14, 2026 and withdrew its case against OptumRx from adjudication to consider a proposed consent agreement. Express Scripts is also among the defendants in the insulin pricing lawsuit filed by the Texas Attorney General in October 2024.

Cite this report

The Precedent. "FTC settles insulin rebate case with Cigna's Express Scripts under sweeping consent order." August 25, 2026. https://theprecedent.org/article/ftc-settles-insulin-rebate-case-with-cignas-express-scripts-under-sweeping-conse

Companies in this report